ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES

The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mayandi, Venkatesh, Goh, Tze Leng Eunice, Rajamani, Lakshminarayanan, Verma, Navin Kumar, Beuerman, Roger Wilmer
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Mayandi, Venkatesh
Goh, Tze Leng Eunice
Rajamani, Lakshminarayanan
Verma, Navin Kumar
Beuerman, Roger Wilmer
description The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2019276505A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2019276505A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2019276505A13</originalsourceid><addsrcrecordid>eNrjZLB09Avx9PV0DvJ38nT0UQhwDQjxdHENVnD29w0I8gz29HNXcA0I9vTx91PwiQRyXRWCXIM9XUJdg3kYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXxosJGBoaWRuZmpgamjoTFxqgBkVion</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES</title><source>esp@cenet</source><creator>Mayandi, Venkatesh ; Goh, Tze Leng Eunice ; Rajamani, Lakshminarayanan ; Verma, Navin Kumar ; Beuerman, Roger Wilmer</creator><creatorcontrib>Mayandi, Venkatesh ; Goh, Tze Leng Eunice ; Rajamani, Lakshminarayanan ; Verma, Navin Kumar ; Beuerman, Roger Wilmer</creatorcontrib><description>The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification.</description><language>eng</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20190912&amp;DB=EPODOC&amp;CC=US&amp;NR=2019276505A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20190912&amp;DB=EPODOC&amp;CC=US&amp;NR=2019276505A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Mayandi, Venkatesh</creatorcontrib><creatorcontrib>Goh, Tze Leng Eunice</creatorcontrib><creatorcontrib>Rajamani, Lakshminarayanan</creatorcontrib><creatorcontrib>Verma, Navin Kumar</creatorcontrib><creatorcontrib>Beuerman, Roger Wilmer</creatorcontrib><title>ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES</title><description>The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB09Avx9PV0DvJ38nT0UQhwDQjxdHENVnD29w0I8gz29HNXcA0I9vTx91PwiQRyXRWCXIM9XUJdg3kYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXxosJGBoaWRuZmpgamjoTFxqgBkVion</recordid><startdate>20190912</startdate><enddate>20190912</enddate><creator>Mayandi, Venkatesh</creator><creator>Goh, Tze Leng Eunice</creator><creator>Rajamani, Lakshminarayanan</creator><creator>Verma, Navin Kumar</creator><creator>Beuerman, Roger Wilmer</creator><scope>EVB</scope></search><sort><creationdate>20190912</creationdate><title>ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES</title><author>Mayandi, Venkatesh ; Goh, Tze Leng Eunice ; Rajamani, Lakshminarayanan ; Verma, Navin Kumar ; Beuerman, Roger Wilmer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2019276505A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>Mayandi, Venkatesh</creatorcontrib><creatorcontrib>Goh, Tze Leng Eunice</creatorcontrib><creatorcontrib>Rajamani, Lakshminarayanan</creatorcontrib><creatorcontrib>Verma, Navin Kumar</creatorcontrib><creatorcontrib>Beuerman, Roger Wilmer</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Mayandi, Venkatesh</au><au>Goh, Tze Leng Eunice</au><au>Rajamani, Lakshminarayanan</au><au>Verma, Navin Kumar</au><au>Beuerman, Roger Wilmer</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES</title><date>2019-09-12</date><risdate>2019</risdate><abstract>The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2019276505A1
source esp@cenet
subjects CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
title ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A10%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Mayandi,%20Venkatesh&rft.date=2019-09-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2019276505A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true